Index

Note: Page numbers of article titles are in **bold face** type.

ABO INCOMPATIBILITY, in immune haemolytic anaemia, 44–45
Alpha thalassaemias, 54–55
Amniotic fluid, use in prenatal diagnosis of haematological disease, 210–211
Anaemia—
  immune haemolytic, 39–46, 161–162
    ABO incompatibility in, 44–45
    drug-induced, 46
    due to maternal disease, 45–46
    minor blood group incompatibility, 45
    Rh haemolytic disease in, 39–44
  in haematological complications of bacterial infection, 184–191
  in haemolysis, 35–36
  in premature infants, nutritional factors contributing to, 9–16
  microangiopathic haemolytic, 46–47
  neonatal—
    diagnosis of, 29
    management of, 30–31
    secondary to blood loss, **19–34**
  of prematurity—
    role of folic acid in, 14–16
    role of iron in, 10–12
    role of vitamin E in, 12–14
  physiological, of infancy and the anaemia of prematurity, **3–18**
  sickle cell, 56–57
Antenatal diagnosis of haematological disorders—'1978', **195–216**
Antibody—
  neonatal immune function, 123–126
    IgA, 125
    IgG, 123–125
    IgM in congenital infections, 126
  transfer to intrinsic factor, in maternal autoimmune disease, 163–164
Autoimmune disease, maternal, 160–164
  congenital haemolytic anaemia, 161–162
  congenital neutropenia, 163
  congenital thrombocytopenia, 162–163
  transfer of antibody to intrinsic factor, 163–164
  transfer of lupus erythematosus (LE) factor, 163

BACTERIAL SEPSIS, *see also* Infection,—
  diagnosis of, 183
  disseminated intravascular coagulation (DIC) in, 187
  effect on blood coagulation systems of, 187–191
Beta thalassaemias, 56
Bleeding, intrapulmonary and intraventricular, in the ill neonate, 102–103
Blood—
  coagulation systems—
    disseminated intravascular coagulation (DIC) in neonatal sepsis, in, 187
    effect of bacterial sepsis on, 187–190
    haematological complications of bacterial infection in, 184–191
    thrombocytopenia in, 184–187
  fetal, for prenatal diagnosis—
    of haemoglobinopathies, 195–206
    of other diseases, 207–211
      plasma in, 210
      platelets in, 210
      red cells in, 208
      white cells in, 208–210
  loss, in the newborn—
    clinical and laboratory manifestations of, 27–29
    iatrogenic, 26–27
    neonatal anaemia secondary to, **19–34**
    obstetric accidents, malformations of the placenta and cord as causes of, 24–25
      placental alterations in, 25
      umbilical vessels in, 24
    occult haemorrhage prior to birth or during delivery, as cause of, 21–24
      fetomaternal, 21–23
      fetoplacental, 23–24
      twin-to-twin transfusion, 23
  maternal, in prenatal diagnosis of haematological diseases, 211
  smear, peripheral, in haemolysis, 36–37
  vessels, in the normal neonate, 85–86

C-REACTIVE PROTEIN determination, in diagnosis of bacterial infection, 183

Cell movement—
chemotactic factor deficiencies in, 135
inhibition of leucocyte motility in vitro in, 134–135
in neonatal leucocyte function and dysfunction, 132–138
intrinsic abnormalities in, 133–134
Cellular immunity, in neonatal immune function, 126–130
delayed skin sensitivity in, 129–130
development of, 126–127
effector functions of, 128–129
lymphocyte proliferative response in, 128
lymphocyte type and number in, 127–128
Chemotactic factor deficiencies, 135
Chemotaxis, *see* Cell movement
Coagulation—
disseminated intravascular (DIC), 120
in the ill neonate, 97–101
neonatal: normal physiology and pathophysiology, **85–109**
proteins, in the normal neonate, 88–91
thrombocytopenia, 184–187
Congenital leukaemia—
aetiology of, 148
and the neonatal myeloproliferative disorders associated with Down's syndrome, **147–154**
clinical manifestations and prognosis of, 148–149
differential analysis in, 149–152
bacterial infections, 150
congenital infections, 150
haemolytic disease, 150
myeloproliferative disorders, 150–152
neuroblastoma, 150
incidence of, 147
laboratory findings in, 149
treatment of, 152
Cord, umbilical—
haemoglobin values in term and premature infants, 3–9
malformations of the, 24
Cytomegalovirus—
associated with haemolytic disease, 46
haematological features of maternal infection with, 157–158
in differential diagnosis of congenital leukaemia, 150

DIABETES MELLITUS, in maternal metabolic disorders, 165–166
Disseminated intravascular coagulation (DIC), 120
in neonatal bacterial sepsis, 187
in the ill neonate, 97–101
Down's syndrome—
congenital leukaemia and the neonatal myeloproliferative disorders associated with, **147–154**
in differential diagnosis of congenital leukaemia, 150–152
Drug ingestion, 166–170
and defective haemostasis, 168–169
deficient procoagulant activity in, 168
thrombocytopenia in, 168–169
qualitative platelet abnormalities in, 169
and haemolytic disease, 166–168
associated with G-6-PD deficiency, 166–167
immune, 167–168
and methaemoglobinaemia, 170

ELLIPTOCYTOSIS, hereditary, 49
Enzyme abnormalities of red blood cells—
glucose-6-phosphate dehydrogenase (G6PD) deficiency, 50–52
pyruvate kinase (PK) deficiency, 52
Erythroblastosis fetalis, *see* Rh haemolytic disease
Erythrocyte sedimentation rate, in diagnosis of bacterial infection, 182

FETAL BLOOD—
perenatal diagnosis using—
haemoglobinopathies, 195–206
other diseases, 207–211
plasma in, 210
platelets in, 210
red cells in, 208
white cells in, 208–210
haemoglobin in, in haemolysis, 53
Fetomaternal haemorrhage, 21–23
Fetoplacental haemorrhage, 23–24
Fetoscopy, in prenatal diagnosis of haematological diseases, 211
Fibroblasts, use of in prenatal diagnosis of haemoglobinopathies, 206–207
Folic acid, role of in anaemia of prematurity, 14–16

GAMMA THALASSAEMIA, 56
Giant haemangioma, 119
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 50–52
in haemolytic disease due to maternal drug ingestion, 166–167
Gower-1 haemoglobin, 53
Gower-2 haemoglobin, 53

HAEMANGIOMA, giant, 119

Haematological abnormalities, neonatal, associated with maternal disease, 155–173
Haematological normal values in newborn period, 19–20
Haemoglobin—
A, 53
cord values in term and premature infants, 3–9
disorders, due to haemolysis, 53
fetal, 53
Gower-1, 53
Gower-2, 53
in unstable haemoglobinopathies, 57–58
F-Poole, 58
Harsharon, 58
physiological factors affecting level of—
in premature infants, 3–9
in term infants, 3–9
Portland, 53
Haemoglobinopathies—
prenatal diagnosis of—
using fetal blood, 195–206
background to, 195–198
application of, 198–206
using fibroblasts, 206–207
unstable, 57–58
haemoglobin F-Poole in, 58
haemoglobin Hasharon in, 58
Haemolysis—
associated with infection, 46
associated with vitamin E deficiency, 47–48
clinical features in newborn infants, 35–37
anaemia and reticulocytosis, 35–36
hyperbilirubinaemia, 36
peripheral blood smear, 36–37
reduced levels of haptoglobin, 36
drug induced, 166–168
associated with G-6-PD deficiency, 166–167
immune haemolytic disease and, 46, 167–168
due to haemoglobin disorders, 53–38
in differential diagnosis of congenital leukaemia, 150
in infancy, **35–61**
secondary to neonatal anaemia, 19
therapeutic considerations, 37–38
Haemolytic anaemia—
congenital autoimmune, 161–162
microangiopathic, 46–47
Haemophilia, and other inherited clotting factor deficiencies, in the well newborn infant, 95–96
Haemorrhage—
internal, in the newborn, 25–26
in the ill neonate, 97–103
disseminated intravascular coagulation (DIC) in, 97–101
due to liver disease, 101–102
intrapulmonary and intraventricular bleeding, 102–103
in the well newborn infant, 94–97
haemophilia and other inherited clotting factor deficiencies, 95–96
vitamin K deficiency in, 94–95
with platelet disorder, 96–97
occult, prior to or during delivery, 21–24
fetomaternal, 21–23
fetoplacental, 23–24
twin-to-twin transfusion, 23
Haemostasis—
defective, due to maternal drug ingestion, 168–169
deficient procoagulant activity in, 168
thrombocytopenia, 168–169
qualitative platelet abnormalities, 169
in the normal neonate, 85–91
Haptoglobin, reduced levels in haemolysis, 36
Herpes simplex—
associated with haemolytic disease, 46
haematological features of maternal infection, 159–160
Histiocytosis, 113
Hydrops fetalis, 54
Hyperbilirubinaemia—
in haemolysis, 36
in maternal metabolic disorders, 166
Hyperviscosity syndrome, 63–64
aetiology of, 64–68
and polycythaemia, in newborn infants, **63–74**
laboratory evaluation of, 71–72
pathophysiology of, 68–71
treatment of, 72–73

IMMUNE DISORDERS—
haemolysis, drug-induced, 46, 167–168
thrombocytopenia, 114–120
Immunoglobulin, in antibody immune system—
IgA, 125
IgG, 123–125
IgM, 126
Immunological function and leucocyte disorders in newborn infants, **123–146**
Immunoneutropenia, 130–131
Infancy, *see also* Neonate,—
haemolytic disorders in, **35–61**
physiological anaemia of, and the anaemia of prematurity, **3–18**
Infantile pyknocytosis, 49–50
Infection—
bacterial—

Infection—bacterial (*continued*)
changes in blood neutrophils during, 176–182
absolute band (non-segmented) counts, 177–180
changes in morphology, 180–181
in neutrophilia, 176
in neutropenia, 176–177
response of, 181–182
haematological complications of, in newborn infants, 184–191
anaemia and jaundice in, 191
platelets and the blood coagulation systems in, 183–191
disseminated intravascular coagulation (DIC) in neonatal bacterial sepsis, in, 187
effect of bacterial sepsis on, 187–190
thrombocytopenia, 184–187
haematological tests in the diagnosis of, 175–184
C-reactive protein determination, 183
erythrocyte sedimentation rate, 182
NBT test, 183
plasma fibrinogen levels, 182
serum IgM levels, 183
the haematology of, in newborn infants, **175–193**
cytomegalovirus, 157–158
herpes simplex, 159–160
malaria, 160
rubella, 156–157
syphilis, 159
toxoplasmosis, 158–159
Intracellular killing, 137–138
Intrapulmonary bleeding, in the ill neonate, 102–103
Intravascular coagulation, disseminated (DIC), 120
in the ill neonate, 97–101
Intraventricular bleeding, in the ill neonate, 102–103
Iron, role of in anaemia of prematurity, 10–12
Isoimmune neonatal purpura, 116–118

JAUNDICE, in haematological complications of bacterial infection, 184–191

LEUCOCYTE—
disorders, and immunological function in newborn infants, **123–146**
function and dysfunction, neonatal, 132–138
cell movement (chemotaxis and random mobility), 133–135
chemotactic factor deficiencies in, 135
LEUCOCYTE—(*continued*)
inhibition of leucocyte motility in vitro in, 134–135
intrinsic abnormalities in, 133–134
ingestion in, 137–138
intracellular killing, 137–138
phagocytic cell recognition in, 135
opsonization, 135–137
Leukaemia, congenital—
aetiology of, 148
and the myeloproliferative disorders associated with Down's syndrome, **147–154**
clinical manifestations and prognosis of, 148–149
differential diagnosis in, 149–152
incidence of, 147
laboratory findings in, 149
resulting from decreased platelet production, 113
treatment of, 152
Liver disease, haemorrhage due to, in the ill neonate, 101–102
Lupus erythematosus (LE) factor, in maternal autoimmune disease, 163
Lymphocyte—
effector functions of, 128–129
proliferative response of, 128
type and number in newborn infants, 127–128

MALARIA, congenital, 160
Marble bone disease, *see* Osteopetrosis
Maternal autoimmune disease, 160–164
congenital haemolytic anaemia and, 161–162
congenital neutropenia and, 163
congenital thrombocytopenia and, 162–163
transfer of lupus erythematosus (LE) factor in, 163
transfer of antibody to intrinsic factor in, 163–164
Maternal blood, in prenatal diagnosis of haematological disease, 211
Maternal disease—
as cause of immune haemolytic anaemia, 45–46
neonatal haematological abnormalities associated with, 155–173
Maternal drug ingestion, 166–170
and defective haemostasis, 168–169
deficient procoagulant activity in, 168
thrombocytopenia in, 168–169
qualitative platelet abnormalities in, 169
and haemolytic disease, 166–168
associated with G-6-PD deficiency, 166–167

Maternal drug ingestion—(*continued*)
immune, 167–168
and methaemoglobinaemia, 170
Maternal infections, haematological features of in the neonate, 155–160
congenital cytomegalovirus (CMV), 157–158
congenital malaria, 160
congenital rubella, 156–157
congenital syphillis, 159
congenital toxoplasmosis, 158–159
herpes simplex in, 159–160
Maternal malignant tumours, 165
Maternal metabolic disorders, 165–166
diabetes mellitus, 165–166
hyperbilirubinaemia, 166
Maternal nutritional deficiencies, 164
Megakaryocytic hypoplasia, congenital, 112–113
Membrane disorders, hereditary, of RBC, 48–50
elliptocytosis in, 49
infantile pyknocytosis in, 49–50
spherocytosis (HS) in, 48–49
stomatocytosis in, 50
xerocytosis in, 50
Metabolic disorders, maternal, 165–166
diabetes mellitus, 165–166
hyperbilirubinaemia, 166
Methaemoglobin, biochemistry of its formation and reduction, 75–78
Methaemoglobinaemia—
due to maternal drug ingestion, 170
in the newborn infant, **75–83**
aetiology of, 78
clinical features, of, 79
diagnosis of, 79–80
therapy for, 80–81
Microangiopathic haemolytic anaemia, 46–47
Minor blood group incompatibility, in immune haemolytic anaemia, 45
Myeloproliferative disorders—
in differential diagnosis of congenital leukaemia, 150–152
neonatal, associated with Down's syndrome, and congenital leukaemia, 147–154

NBT TEST, in diagnosis of bacterial infection, 183
Neonate—
aetiology of blood loss in, 20–27
anaemia in, secondary to blood loss, 19–34
bleeding, diagnostic approach to, 91–94
history of, 91–92
laboratory studies for, 92–94
Neonate—(*continued*)
physical examination of, 92
clinical and laboratory manifestations of blood loss in, 27–29
coagulation in, normal physiology and pathophysiology, 85–109
haematological abnormalities of, associated with maternal disease, **155–173**
haematological complications of bacterial infection in, 184–191
in anaemia and jaundice, 191
in platelets and the blood coagulation systems, 184–191
immune function, 123–130
antibody immune system in, 123–126
cellular immunity in, 126–130
leucocyte disorders and immunological function in, **123–146**
methaemoglobinaemia in, **75–83**
normal—
blood vessels in, 85–86
coagulation proteins in, 88–91
haematological values in, 19–20
haemostasis in, 85–91
platelets in, 86–88
polycythaemia and the hyperviscosity syndrome in, **63–74**
the haematology of bacterial infection in, 175–193
Neuroblastoma, 150
Neutropenia—
chronic, 131–132
congenital autoimmune, 130–131, 163
neutrophil numbers during bacterial infection in, 176–177
Neutrophilia, neutrophil numbers during bacterial infection in, 176
Neutrophils—
changes during bacterial infection in, 176–182
in neutropenia, 176–177
in neutrophilia, 176
changes in absolute band (non-segmented) counts, 177–180
changes in morphology, 180–181
response to bacterial infection of, 181–182
Newborn, *see* Neonate
Nutritional deficiencies, maternal, 164

OBSTETRIC ACCIDENTS, 24–25
Occult haemorrhage, prior to or during delivery, 21–24
fetomaternal, 21–23
fetoplacental, 23–24
twin-to-twin transfusion, 23
Opsonization, 135–137
Osteopetrosis, 121

PERIPHERAL BLOOD SMEAR, in haemolysis, 36–37
Phagocytosis, 137–138
  cell recognition in, 135
  intracellular killing, 137–138
Physiological anaemia of infancy and the anaemia of prematurity, **3–18**
Placenta, malformations of, 25
Plasma—
  fibrinogen levels in, 182
  in fetal blood, 210
Platelets—
  haematological complications of bacterial infection in, 184–191
  in fetal blood, 210
  in the normal neonate, 86–88
  qualitative abnormalities due to maternal drug ingestion, 169
Polycythaemia—
  aetiology of, 64–68
  and the hyperviscosity syndrome in newborn infants, 63–74
  laboratory evaluation of, 71–72
  pathophysiology of, 68–71
  treatment of, 72–73
Portland haemoglobin, 53
Premature infants—
  anaemia of, 3–18
  considerations in the care of, 16–17
  nutritional factors contributing to anaemia in, 9–16
Procoagulant activity, deficient, due to maternal drug ingestion, 168
Proteins, coagulation, in the normal neonate, 88–91
Purpura—
  isoimmune neonatal, 116–118
  maternal drug induced, 119
  thrombocytopenic neonatal, secondary to maternal idiopathic thrombocytopenic purpura, 116–118
Pyruvate kinase (PK) deficiency, 52

RANDOM MOBILITY, *see* cell movement
Red blood cells—
  enzyme abnormalities in, 50–58
  hereditary membrane disorders of, 48–50
    elliptocytosis, 49
    pyknocytosis, 49–50
    spherocytosis (HS), 48–49
    stomatocytosis, 50
    xerocytosis, 50
  in fetal blood, 208
Reticulocytosis, in haemolysis, 35–36
Rh haemolytic disease, 39–44
Rubella—
  associated with haemolytic disease, 46
  congenital, haematological features of maternal infection in, 156–157
  in differential diagnosis of congenital leukaemia, 150

SERUM IMMUNOGLOBULIN M levels, in diagnosis of bacterial infection, 183
Sickle cell anaemia, 56–57
Skin sensitivity, delayed in neonatal immune function, 129–130
Spherocytosis, hereditary (HS), 48–49
Stomatocytosis, hereditary, 50
Syphilis—
  associated with haemolytic disease, 46
  congenital, haematological features of maternal infection in, 159
  in differential diagnosis of congenital leukaemia, 150

THALASSAEMIA SYNDROMES, 54–56
  alpha thalassaemias, 54–55
  beta thalassaemia, 55
  gamma thalassaemia, 55
Thrombocytopenia—
  associated with giant haemangioma, 119
  congenital autoimmune, 162–163
  due to both decreased production and increased destruction, 120–121
    in infection, 120–121
    osteopetrosis, 121
  due to maternal drug ingestion, 119, 168–169
  haematological complications of bacterial infection in, 184–187
  immune, associated with increased peripheral destruction, 114–120
    isoimmune neonatal purpura, 116–118
    secondary to maternal idiopathic thrombocytopenic purpura, 115–116
  resulting primarily from decreased production, 112–114
    congenital leukaemias and histiocytosis, 113
    congenital megakaryocytic hypoplasia, 112–113
Thrombosis, localized large vessel, 103–104
Toxoplasmosis—
  associated with haemolytic disease, 46
  congenital, haematological features of maternal infection, 158–159
  in differential diagnosis of congenital leukaemia, 150
Transfusion—
  criteria for, in the high risk infant, 26–27
  twin-to-twin, 23
Tumours, maternal malignant, 165

ULTRASOUND, in prenatal diagnosis of haematological diseases, 211

VITAMIN—
E—
deficiency, associated with haemolysis, 47–48
role of, in anaemia of prematurity, 12–14

VITAMIN—(*continued*)
K deficiency, in the well newborn infant, 94–95

WHITE BLOOD CELLS, in fetal blood, 208–210, *see also* Leucocytes and Lymphocytes

XEROCYTOSIS, hereditary, 50

Index

ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)—
  cell kinetics during, 341–346
    use of in designing treatment protocols, 350–356
  chromosome abnormalities in, 397–402
    clinical correlation of, 399
    evolution of, 399
    frequency of, 397
  immunotherapy for, 278–281, 352
  treatment of—
    in adults, 266–268
    in children, 245–256
      high risk, 252–253
      standard risk, 247–252
        CNS prophylaxis, 248–249
        continuation therapy, 249–251
        immunotherapy, 252
        remission induction, 247–248
        treatment of relapse, 251–252
Acute myeloblastic leukaemia (AML)—(*see also* Acute non-lymphoblastic leukaemia)
  treatment of, in children, 253–255
    cessation of therapy, 255
    CNS prophylaxis, 254
    continuation therapy, 254, 255
    remission induction, 254
Acute non-lymphoblastic leukaemia (ANLL)—
  as a second malignancy, 395–397
  cell kinetics during, 341–346
    use of in designing treatment protocols, 350–357
  chromosome abnormalities in, 395–397
    marker chromosomes, 396
    significance of, 402–403
  treatment of, in adults, 263–266
    induction of remission, 263
    maintenance therapy, 263–265
    new agents used in, 266
Acute promyelocytic leukaemia, 392
Adriamycin, 352
Anaemia, in patients with leukaemia, 407–408
  red cell transfusions for, 407–408
Aneuploidy, in acute leukaemia, 394–395, 397
Antigens associated with leukaemia, *see* Leukaemia-associated antigens
L-Asparaginase, 247–248, 250, 262, 267, 268
Aspergillus, 260–261
5-Azacytidine, 266

BANDING PATTERNS of chromosomes in leukaemia, 388–397
Bart's–Marsden trial, 281–287
BCG in therapy of acute leukaemia, 279–281, 288–289
B-lymphocyte antigens, 367–368
Blood component therapy, **407–419**
  granulocyte transfusions, 298, 413–419
    indications for, 415–419
    methods of, 414–415
  platelet transfusions, 409–413
    indications for, 411–412
    measurement of response to, 410–411
    platelet function, 409–410
    sensitization to platelets, 412–413
  red cell transfusions, 407–408
Blood groups—
  in selection of bone marrow donors, 296–297
  red cell transfusion and, 407–408
Bone involvement in acute leukaemia, 334
Bone marrow transplantation in acute leukaemia, **295–309**
  allogeneic, 291–292, 300–306
  documentation of engraftment, 298
  graft rejection, 301
  graft versus host disease (GVHD), 301–302
    effect on leukaemia, 305–306
  granulocyte transfusions in recipients, 298
  histocompatibility and donor selection, 296–297
  immunological reactivity, 303–304
  immunosuppression after transplants, 299
  infections in recipients, 302–303
  long-term survival, 306–307
  preparation of recipient, 297–298
  recurrent leukaemia, 304–305
  technique of, 297
  twin transplants, 299–300

CANDIDA, 260–261
Cell kinetics in leukaemia, **339–357**
  and design of treatment protocols, 350–356
  and prognosis, 343–344

Cell kinetics in leukaemia (*continued*)
fine tuning in combination chemotherapy, 247–350
in remission, 340–341
mathematical models of, 344–346
Central nervous system, *see* CNS
Chromosome abnormalities, *see* Cytogenetics of acute leukaemia
CNS involvement in leukaemia—
prevention of CNS relapse, 314–322
influence of haematological relapse, 321
irradiation dosage, 314–322
systemic chemotherapy, 318–320
treatment of CNS relapse, 229–230, 314–322, 322–325
in AML in children, 254
in standard risk ALL in children, 248–249
influence of on haematological relapse, 324–325
prognostic factors, 324
Corynebacterium parvum, 278
Cycle-non-specific drugs, 350–356
Cycle-specific drugs, 350–356
Cyclophosphamide, 248, 297, 356
Cytogenetics of acute leukaemia, **385–404**
aneuploidy, 394–395, 397
loss of a sex chromosome, 392
chromosome bands, 388–397
historical discussion of, 387
in ALL, 397–402
clinical correlation, 399
evolution of, 399
frequency of abnormalities, 397
in ANLL, 395–397
marker chromosomes in, 396
significance of abnormalities in, 402–403
Philadelphia chromosome (Ph′), 400–402
structural abnormalities, 388–394
techniques used in study of, 386–387
translocations, 388–394, 397
Cytosine arabinoside, 252, 254, 262–264, 268, 350, 356

DAUNOMYCIN, 248, 254, 262–263, 268, 350, 353
Drug resistance, in patients with leukaemia, 269

EXTRAMEDULLARY LEUKAEMIA, **313–334**
bone involvement, 334
CNS involvement—
prevention of 314–322
influence of haematological relapse, 321
irradiation dosage, 318
systemic chemotherapy, 318–320
Extramedullary leukaemia (*continued*)
CNS involvement (*continued*)
treatment of, 322–325
in AML in children, 254
in standard risk ALL in children, 248–249
influence of on haematological relapse, 324–325
prognostic factors, 324
heart involvement, 334
kidney involvement, 334
lung involvement, 334
ocular involvement, 334
testicular and ovarian leukaemia, 325–334
factors influencing, 327, 329
frequency of, 325–327
influence of systemic treatment on, 332–333
time of, 330
treatment of, 330–332

FRIEND LEUKAEMIA VIRUS, 379–380

GRAFT VERSUS HOST DISEASE (GVHD), 301–302
effect of on leukaemia, 305–306
Granulocyte transfusions, 298, 413–419
indications for, 415–419
methods of, 414–415

HAEMORRHAGE, 409–412
Heart involvement in acute leukaemia, 334
Histocompatibility antigens—
and granulocyte transfusions, 418–419
and platelet transfusions, 412–413
in selection of bone marrow donors, 296–297

IMMUNOTHERAPY of acute leukaemia, **275–292**
in ALL, 278–281
BCG as a remission treatment, 279–280
BCG and cells as a remission treatment, 280–281
in children, 252
Mathé's trial, 278–279
in AML, 281–292
BCG as sole agent in, 288–289
in children, 254
mechanisms of, 287–288
studies in progress on, 289–292
the Bart's–Marsden trial, 281–287
Induction of remission, 229
in AML in children, 254
in ANLL in adults, 263
in standard risk ALL in children, 247–248
Infections, in patients with leukaemia, 260–262
granulocyte transfusions and, 413–419
in bone marrow transplant recipients, 298, 302–303

Iritis in acute leukaemia, 334
Irradiation, in treatment of CNS leukaemia, 248–249, 389–390, 402–403

KIDNEY—
failure, 262
involvement in acute leukaemia, 334

LEUKAEMIA—
ALL, *see* Acute lymphoblastic leukaemia
AML, *see* Acute myeloblastic leukaemia
ANLL, *see* Acute non-lymphoblastic leukaemia
antigens associated with, *see* Leukaemia-associated antigens
APL, *see* Acute promyelocytic leukaemia
blood component therapy for, *see* Blood component therapy
chromosome abnormalities in, *see* Cytogenetics of acute leukaemia
classification of, 228
extramedullary, *see* Extramedullary leukaemia
incidence of, 228
treatment of, 229–230
in adults, **259–270**
in children, **245–256**
trials in, *see* Trials in leukaemia
viruses, in aetiology of, 278–280
Leukaemia-associated antigens, **363–381**
B-lymphocyte (Ia-like) antigens, 367–368
cell-mediated immune responses to, 363–364
detection by xeno-antisera, 368–378
humoral immune responses to, 364–367
viral antigens, 378–380
Lung involvement in acute leukaemia, 334

MAINTENANCE THERAPY for acute leukaemia, 230
in AML in children, 249–251
in ANLL in adults, 263–265
in standard risk ALL in children, 254–255
Marker chromosomes, 396
Mathé's trial, 278–279
6-Mercaptopurine, 250, 254, 267
Methotrexate, 248, 250–254, 314, 318, 323, 325, 332, 356
Mortality statistics, 227–228

NEOCARZINOSTATIN, 266

OCULAR INVOLVEMENT in acute leukaemia, 334
Oncogenic viruses, 278–280
Ovarian leukaemia, 325–327

PHILADELPHIA (Ph') CHROMOSOME, 400–402
Platelet transfusions, 409–413
indications for, 411–412
Platelet transfusions (*continued*)
measurement of response to, 410–411
platelet function, 409–410
sensitization to platelets, 412–413
Pneumonia, in patients with acute leukaemia, 260–261
Polysomy, 394–395
Prednisone, 247–248, 250, 254, 262, 266–268, 352
Pseudomonas aeruginosa, 260

RED CELL TRANSFUSIONS, 407–408
Remission in acute leukaemia, 340–341
induction of, 229
in AML in children, 254
in ANLL in adults, 263
in standard risk ALL in children, 247–248
Renal failure, 262
Risk factors for acute leukaemia, 246–247

SMOULDERING LEUKAEMIA, 259
SV-40, 379

TESTICULAR AND OVARIAN LEUKAEMIA, 325–334
factors influencing, 327–329
frequency of, 325–327
influence of systemic treatment on, 332–333
time of, 330
treatment of, 330–332
6-Thioguanine, 254, 264, 267, 350
Thrombocytopenic haemorrhage, 409–412
Transfusions, *see* Blood component therapy
Translocations, 388–394, 397
Transplantation, *see* Bone marrow transplantation
Trials in leukaemia, design and evaluation of, **227–243**
allocation of patients to treatment groups, 234
analysis of results, 238–243
presentation of data, 242–243
duration of trial, 236–238
eligibility of patients for, 233
end points, determination of, 231
objectives, determination of, 231–232
protocol, development of, 231
risk groups, separation of, 235
sample size, 234–235, 236–238

VINCRISTINE, 247–248, 250, 254, 262, 266–268, 352, 356
Virus, in aetiology of acute leukaemia, 378–380
VP16–213, 266

WHEEL-SPINNING LEUKAEMIA, 259

XENO-ANTISERA, 368–378

Index

Note: Page numbers of article titles are in **bold face** type.

ACUTE LYMPHOCYTIC LEUKAEMIA, 451
Adrenergic drugs, effects of on bone marrow, 562–564
Agranulocytosis, drug-induced, 501–504
  clinical manifestations of, 502
  pathophysiology of, 502–504
  treatment of, 504
Amegakaryocytic thrombocytopenia, 449
Anaemia—
  aplastic—
    acquired, 435–445, 450
    aetiology of, **431–465**
      cellular factors in, 457
      humoral factors in, 456–457
      microenvironment in, 456
      stem cells in, 456
    androgen therapy of, **571–585**
    animal models of, 434
    bone marrow culture techniques in, **487–499**
    bone marrow transplantation for treatment of, **597–609**
    CFU-C growth in, 489–490
    classification of, **431–465**
    clinical single cell deficiencies in, 451–455
      neutropenia, 454–455
      pure red cell aplasia, 451–454
      thrombocytopenia, 455
    congenital disorders and, 490–491
    drug-related, 441–443
    familial, 447–449, 451
    hepatitis-associated, 444
    idiopathic, 441
      in vitro studies in, 488–489
    immune aetiology of, 493–497
    infection-induced, 444
    paroxysmal nocturnal haemoglobinuria in, **541–553**
      therapy for, 548–549
    post-hepatitis, 493
    pregnancy and, 444–445
    prognostic factors in, **467–474**
      blood studies, 469–470
      bone marrow studies, 470
      clinical factors, 469
Anaemia (*continued*)
  aplastic (*continued*)
    prognostic factors in (*continued*)
      factors affecting outcome, 469
      patient selection, 467–468
      prognostic index, 471–473
      radioisotope studies, 471
      survival data, 468–469
    radiation-induced, 443–444
    severe, 599
      prospective study of effects of androgens or transplantation, **587–595**
    supportive measures for, **623–637**
      granulocyte transfusions, 628–630
      platelet transfusions, 624–628
      protective isolation, 631–632
      red cell transfusions, 623–624
      treatment of infections, 632–633
    thymoma and, 445
    toxic induction of, 443
    treatment of by antilymphocyte globulin, **611–621**
  Fanconi's, 446–447, 450
Androgens—
  immune effects of, 578–579
  in therapy for aplastic anaemia, **571–585**
    diagnostic procedures, 572–573
    5β metabolites, 576–578
    uses of, 573–576
  leukaemia and, 579–581
  prospective study on effects of on aplastic anaemia, **587–595**
    study design, 587–589
Antilymphocyte globulin, 612
  in treatment of aplastic anaemia, **611–621**
    clinical studies, 612
    experimental studies, 612
Aplasia, pure red cell, 451–454
Aplastic anaemia, *see* Anaemia, aplastic

BLOOD, studies on in prognosis of aplastic anaemia, 469–470
Bone marrow—
  culture techniques in aplastic anaemia, **487–499**

Bone marrow (*continued*)
depression, drug-induced, 491–493
failure, immunopathology of, **475–486**
antibody mediated, 479–480
cell mediated, 480–482
immune basis of, 479–482
infusion of, with antilymphocyte globulin in treatment of aplastic anaemia, **611–621**
pharmacological stimulation of function of, **555–569**
adrenergic drugs, 562–564
cholinergic drugs, 562–564
steroids in culture, 561–562
steroids in vivo, 558–560
replacement, thrombocytopenia and, 527
studies on in prognosis of aplastic anaemia, 470
transplantation of, **597–609**
clinical results of, 599–605
early attempts at, 597–598
effects of in severe aplastic anaemia, **587–595**
graft rejection, 601–604
graft-versus-host disease (GVHD), 604–605
infections associated with, 605
principles of, 598–599

CHEDIAK–HIGASHI SYNDROME, 517–518
clinical manifestations of, 517
pathophysiology of, 517–518
treatment of, 518
Cholinergic drugs, effects of on bone marrow, 562–564

DYSKERATOSIS CONGENITA, 449–450

ERYTHROBLASTOPENIA, transient, of childhood, 454

FANCONI'S ANAEMIA, 446–447, 450
Felty's syndrome, 508–510
clinical manifestations of, 508–509
pathophysiology of, 509–510
treatment of, 510

GRAFT-VERSUS-HOST DISEASE (GVHD), 604–605
Granulocyte therapy, support for aplastic anaemia, 628–630

HAEMATOLOGICAL RECOVERY, effects of androgens or transplantation on, **587–595**
Haematopoiesis, 431–434
immune system and, 475–478
organization of system of, 555–557
Haemoglobinuria, paroxysmal nocturnal, in aplastic anaemia, **541–553**
therapy for, 548–549
Hepatitis, in the aetiology of aplastic anaemia, 444, 493

IMMUNE SYSTEM—
in the aetiology of aplastic anaemia, 493–497
relationship to haematopoiesis, 475–478
Immunopathology, marrow failure and, **475–486**
Infection, in the aetiology of aplastic anaemia, 444

LAZY LEUCOCYTE SYNDROME, 514
Leukaemia, androgens and, 579–581
Lupus erythematosus, 480

MARROW, *see* Bone marrow
May–Hegglin anomaly, 528
Megakaryocytopoiesis, decreased, 523–527
hypoplasia, 523–527
congenital, 524–526
toxically induced, 526
viral infections and, 527
marrow replacement and, 527
Megaloblastosis, 528–529

NEUTROPENIA, 454–455, **501–521**
autoimmune, 506–508
pathophysiology of, 508
treatment of, 508
chronic idiopathic, 511–514
clinical description of, 511–512
pathophysiology of, 512–513
treatment of, 513–514
cyclic, 514–516
clinical manifestations of, 514–515
pathophysiology of, 515
treatment of, 516
idiopathic, in vitro studies of, 491
immune, 504–508
isoimmune neonatal (INN), 505–506
pathophysiology of, 506
treatment of, 506
primary splenic, 516

PANCYTOPENIA, clinical, 435–451
acquired aplastic anaemia, 435–445
constitutional aplastic anaemia, 445–450
preleukaemia, 450–451
Platelet—
production, ineffective, 527–529
hereditary, 527–528
autosomal dominant thrombocytopenia, 527–528
May–Hegglin anomaly, 528
Wiskott–Aldrich syndrome, 528

Platelet (*continued*)
production (*continued*)
megaloblastosis, 528–529
preleukaemia, 529
support, for aplastic anaemia, 624–628
Pregnancy, aplastic anaemia and, 444–445
Preleukaemia, 450–451, 529

RADIATION, in the aetiology of aplastic anaemia, 443–444
Red cell—
aplasia, 479
support, for aplastic anaemia, 623–624

SHWACHMAN–DIAMOND SYNDROME, 450
Steroid hormones, effects of on bone marrow—
in culture, 561–562
Steroid hormones (*continued*)
in vivo, 558–560

THROMBOCYTOPENIA, 455, **523–539**
autosomal dominant, 527–528
pathophysiology of, 523–529
decreased megakaryocytopoiesis, 523–527
ineffective platelet production, 527–529
production related, course and management of, 529–536
Thymoma, in the aetiology of aplastic anaemia, 445
Transplantation, *see* Bone marrow, transplantation of

WISKOTT–ALDRICH SYNDROME (WAS), 528